Search
Nervgen Pharma Ord Shs
NGENAdd to Watchlist
2.120USD
+0.030+1.44%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
171.78MMarket Cap
LossP/E TTM
More Details of Nervgen Pharma Ord Shs Company
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shs Info
Ticker SymbolNGEN
Company nameNervGen Pharma Corp
IPO dateMar 13, 2019
CEORogers (Adam H)
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
AddressSuite 1703 - 595 Burrard Street
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV7X 1J1
Phone16047225361
Websitehttps://www.nervgen.com/
Ticker SymbolNGEN
IPO dateMar 13, 2019
CEORogers (Adam H)
Company Executives of Nervgen Pharma Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
FAQs
Who are the top five shareholders of Nervgen Pharma Ord Shs?
The top five shareholders of Nervgen Pharma Ord Shs are: Dr. Randall E. Kaye, M.D.
How many institutions hold shares of Nervgen Pharma Ord Shs (NGEN)?
As of 2026Q1, 17 institutions hold shares of Nervgen Pharma Ord Shs, with a combined market value of approximately 350.93K, accounting for 0.44% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 303132.00.